Kiromic BioPharma (NASDAQ:KRBP) Shares Down 7.9% – Time to Sell?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) dropped 7.9% during mid-day trading on Tuesday . The stock traded as low as $1.08 and last traded at $1.08. Approximately 979 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 2,009 shares. The stock had previously closed at $1.17.

Kiromic BioPharma Trading Down 7.9 %

The company’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $1.19. The stock has a market capitalization of $1.70 million, a P/E ratio of -0.31 and a beta of 1.66.

Kiromic BioPharma Company Profile

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.